439 related articles for article (PubMed ID: 26003966)
1. Requirements for blood and blood components intended for transfusion or for further manufacturing use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2015 May; 80(99):29841-906. PubMed ID: 26003966
[TBL] [Abstract][Full Text] [Related]
2. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
[TBL] [Abstract][Full Text] [Related]
3. Current good manufacturing practice for blood and blood components; notification of consignees and transfusion recipients receiving blood and blood components at increased risk of transmitting hepatitis C virus infection ("lookback"). Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Aug; 72(164):48765-801. PubMed ID: 17886394
[TBL] [Abstract][Full Text] [Related]
4. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
[TBL] [Abstract][Full Text] [Related]
5. Revisions to labeling requirements for blood and blood components, including source plasma. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2012 Jan; 77(1):7-18. PubMed ID: 22242229
[TBL] [Abstract][Full Text] [Related]
6. The revision of the European blood directives: A major challenge for transfusion medicine.
Folléa G; Aranko K;
Transfus Clin Biol; 2015 Aug; 22(3):141-7. PubMed ID: 26056039
[TBL] [Abstract][Full Text] [Related]
7. Revisions to the requirements applicable to blood, blood components, and source plasma. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Aug; 66(151):40886-90. PubMed ID: 11732557
[TBL] [Abstract][Full Text] [Related]
8. General requirements for blood, blood components, and blood derivatives; donor notification. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Jun; 66(112):31165-77. PubMed ID: 11725787
[TBL] [Abstract][Full Text] [Related]
9. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597
[TBL] [Abstract][Full Text] [Related]
10. AIDS and the blood supply: an analysis of law, regulation, and public policy.
Salbu SR
Wash Univ Law Q; 1996; 74(4):913-80. PubMed ID: 16273697
[No Abstract] [Full Text] [Related]
11. Transposition of the Blood Directive into national law--the perspective of Portugal.
Gonçalves MH; Muon MC; Gonçalves Jd
Transfus Clin Biol; 2005 Feb; 12(1):18-20. PubMed ID: 15814287
[TBL] [Abstract][Full Text] [Related]
12. Transfusion safety: is this the business of blood centers?
Slapak C; Fredrich N; Wagner J
Transfusion; 2011 Dec; 51(12 Pt 2):2767-71. PubMed ID: 22150688
[TBL] [Abstract][Full Text] [Related]
13. Revisions to the requirements applicable to blood, blood components and source plasma. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Aug; 72(158):45883-88. PubMed ID: 17847577
[TBL] [Abstract][Full Text] [Related]
14. Preparing for inspection: managing regulations and practices surrounding donors with positive infectious disease testing.
Ferschke J
J Clin Apher; 2008; 23(6):191-5. PubMed ID: 18973114
[TBL] [Abstract][Full Text] [Related]
15. Revisions to the requirements applicable to blood, blood components, and source plasma; confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment.
Fed Regist; 2001 Jan; 66(7):1834-7. PubMed ID: 11503754
[TBL] [Abstract][Full Text] [Related]
16. Medicare and Medicaid programs; hospital conditions of participation: laboratory services. Interim final rule with comment period.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2007 Aug; 72(164):48562-74. PubMed ID: 17886393
[TBL] [Abstract][Full Text] [Related]
17. Revisions to the requirements applicable to blood, blood components and source plasma; confirmation of effective date and technical amendment. Direct final rule; confirmation of effective date and technical amendment.
Food and Drug Administration, HHS
Fed Regist; 2008 Feb; 73(27):7463-4. PubMed ID: 18389917
[TBL] [Abstract][Full Text] [Related]
18. [European regulation on blood and blood components].
Sandid I
Transfus Clin Biol; 2010 Dec; 17(5-6):310-4. PubMed ID: 21050786
[TBL] [Abstract][Full Text] [Related]
19. Transposing the E. E. U. Blood Directive into national law. Perspective of Slovenia.
Potocnik M
Transfus Clin Biol; 2005 Feb; 12(1):21-4. PubMed ID: 15814288
[TBL] [Abstract][Full Text] [Related]
20. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
